PsiOxus Therapeutics Moves Into New Facilities
02/05/2012
PsiOxus Therapeutics has opened a new state of the art laboratory at Milton Park as part of its expansion plans. The facility has been designed and equipped as a category two laboratory for the handling of live viruses, and will be key to the continued growth of PsiOxus.
Dr John Beadle, Chief Executive Officer at PsiOxus says: "PsiOxus is developing novel viral based therapies and vaccines, with a particular focus upon the treatment of cancer. As our second product will enter clinical trials later this year we needed to expand our organisation and to design a facility to our own specifications. Milton Park offered us an excellent opportunity to create a facility which would support our growth. This prestigious location is already home to many bio-science innovators and MEPC has fitted out our new lab to our exacting standards."
PsiOxus therapeutics employs world-leading scientists and a highly experienced management team to produce novel cancer therapeutics. MT-102 is the most advanced product and is in mid-stage clinical trials for the treatment of cancer cachexia. The second product, ColoAd1, is an oncolytic virus that will enter clinical trials in 2012.
Jo Szegota, Head of Greenlite leasing at Milton Park, adds: "Milton Park has had a major cluster of bio-science companies for many years and across the park our customers include leaders in the pharma, medical and technology industries. We are extremely pleased to be able to welcome PsiOxus to this successful and thriving scientific community. With MEPC's considerable experience in commercial property and Milton Park's specific knowledge of how a modern laboratory needs to function including the creation of controlled clean air environments such as this, we have created a facility which will make PsiOxus feel they belong here with us."
